Additional file 5: of Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Figure S4. Begg’s and Egger’s tests for comparisons of ORR (A) and DCR (B) associated with pazopanib versus sunitinib. (TIF 1210 kb)